TRAIL及其受體在直腸癌組織中的表達_《中國普外基礎與臨床雜志》

作者：

胡建昆 ¹ , 楊昆 ¹ , 李春梅 ² , 周總光 ³ , 張波 ¹ , 于永揚 ³ , 陳心足 ¹ , 李立 ³ , 陳志新 ¹ , 陳佳平 ¹

1.四川大學華西醫院胃腸外科(成都610041);;
2.四川大學華西第二醫院婦產科(成都610041);;
3.四川大學華西醫院肛腸外科(成都610041);

關鍵詞：

直腸癌腫瘤壞死因子相關凋亡誘導配體免疫組化

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討腫瘤壞死因子相關凋亡誘導配體(TRAIL)及其受體(DR4、DcR1)在正常直腸和直腸癌組織中的表達。
方法在31例直腸癌和20例正常直腸組織中，用免疫組化法檢測TRAIL、DR4和DcR1的蛋白表達。
結果直腸癌組織中TRAIL、DR4和DcR1蛋白的表達陽性率（32.26%、29.03%、0）均低于正常直腸組織（55.00%、70.00%、65.00%），差異均有統計學意義(P=0.015、P=0.000、P=0.000)，TRAIL及其受體的表達與直腸癌臨床病理特征間無關（P gt;0.05）。
結論直腸癌組織中TRAIL、DR4和DcR1的表達低于正常直腸組織，TRAIL及其受體相互作用所誘導的凋亡效應在直腸癌中有所減弱。

引用本文： 胡建昆,楊昆,李春梅,周總光,張波,于永揚,陳心足,李立,陳志新,陳佳平. TRAIL及其受體在直腸癌組織中的表達. 中國普外基礎與臨床雜志, 2009, 16(2): 137-140. doi: 復制

1.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
2.	Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
3.	Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
4.	Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
5.	Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
6.	Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
7.	Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
8.	Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
9.	Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
10.	公偉，　劉軍，梁飛，等.TRAIL受體在胰腺癌中的表達 [Ｊ]. 中國普外基礎與臨床雜志,2006;13(5)： 521.
11.	Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
12.	Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
13.	Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
14.	Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
15.	陳心足，姜坤，胡建昆. TRAIL信號通路在胃癌的研究現狀 [Ｊ]. 中國普外基礎與臨床雜志,2007;14(3)： 371.
16.	Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
17.	公偉，李占元，曾慶東，等.腫瘤壞死因子相關凋亡誘導配體聯合化療藥物殺傷胰腺癌細胞的研究 [Ｊ].中華肝膽外科雜志,2006;12(2)： 111.
18.	Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
19.	Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
20.	Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
21.	Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
22.	Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
3. Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
6. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
7. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
8. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
9. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
10. 公偉，　劉軍，梁飛，等.TRAIL受體在胰腺癌中的表達 [Ｊ]. 中國普外基礎與臨床雜志,2006;13(5)： 521.
11. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
12. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
13. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
14. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
15. 陳心足，姜坤，胡建昆. TRAIL信號通路在胃癌的研究現狀 [Ｊ]. 中國普外基礎與臨床雜志,2007;14(3)： 371.
16. Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
17. 公偉，李占元，曾慶東，等.腫瘤壞死因子相關凋亡誘導配體聯合化療藥物殺傷胰腺癌細胞的研究 [Ｊ].中華肝膽外科雜志,2006;12(2)： 111.
18. Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
19. Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
20. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
21. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
22. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.

《中國普外基礎與臨床雜志》

TRAIL及其受體在直腸癌組織中的表達

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

TRAIL及其受體在直腸癌組織中的表達

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料